Skip to main content
. 2017 Jun 15;17:419. doi: 10.1186/s12885-017-3409-z

Table 2.

Serum-VEGF, serum-bFGF and urinary-bFGF variations, and risk of poor histological response or treatment failure

Risk of poor histological response Risk of treatment failure
Variation between baseline and pre-surgery(T1-T0) Poor Resp./ Na Adjusted Odds Ratio (95%CI)b P value Event / Nc Adjusted Hazard Ratio (95%CI)d P value
Serum VEGF (N = 165) 0.26 0.67
 Q1: −1424 to −284 12 / 44 1 (ref) 16 / 44 1 (ref)
 Q2: −279 to --80 16 / 43 1.55 (0.57–4.2) 16 / 45 1.13 (0.52–2.5)
 Q3: −79 to − + 35 12 / 39 1.39 (0.46–4.2) 12 / 45 0.98 (0.41–2.3)
 Q4: − + 39 to +503 19 / 39 2.63 (0.97–7.1) 12 / 45 0.69 (0.29–1.7)
Serum bFGF (N = 167) 0.85 0.39
 Q1: −257 to −2.5 15 / 44 1 (ref) 14 / 45 1 (ref)
 Q2: −2.4 to +0.8 14 / 44 0.66 (0.21–2.0) 16 / 45 0.66 (0.22–2)
 Q3: +0.9 to +7.2 15 / 40 0.89 (0.3–2.7) 16 / 45 0.45 (0.15–1.3)
 Q4: +7.8 to +92 15 / 39 0.92 (0.3–2.9) 11 / 45 0.45 (0.14–1.4)
Urinary bFGF (N = 73) 0.67 0.20
 Q1: −14.4 to −2.1 5 / 18 1 (ref) 11 / 19 1(ref)
 Q2: −2.1 to +2.4 3 / 17 0.48 (0.08–3.0) 2 / 19 0.17 (0.03–0.89)
 Q3: +2.6 to +12.9 5 / 19 0.70 (0.13–3.9) 6 / 20 0.54 (0.15–1.9)
 Q4: +13.8 to +413 7 / 19 1.32 (0.30–5.7) 9 / 19 0.51 (0.18–1.5)

aPoor Resp. / N: number of patients with poor histological response / number of evaluated patients

bAdjusted odds ratios and their 95% confidence intervals were estimated by multivariable logistic regression, including the biomarker level at diagnosis in quartiles. Results were similar when the model also included the treatment arm (with versus without zoledronate)

cEvents / N: number of events in each subset / number of patients

dHazard ratios of treatment failure and their 95% confidence intervals were estimated in Cox models controlling for the treatment group, initial stage and biomarker level at diagnosis in quartiles